WaveMan
WaveMan · Company
ANVS · Annovis Bio, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ANVS Annovis Bio (ANVS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001477845
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
33
13F, latest reported quarter

What the filings say about ANVS

Insiders, 180 days
+$142.8K net bought
1 buyer

Annovis Bio insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Annovis Bio, Inc. insiders bought a net $142.8K of stock across 23 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Hoffman Michael B
Director
BUY
2026-05-21 SECtraded 2026-05-20
54,933
$104.4K
-55.2%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 buys), the last on Apr 2, 2026.
  • -26.1% median (-14.9% mean) 90-day return after 6 previous buys.
  • The trade is 1.6% of the 3,364,883 shares held after it.
  • No other insider bought within 30 days.
  • 33 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hoffman Michael B bought about $104.4K of ANVS on May 20, 2026; 33 funds added in the latest 13F quarter.
Hoffman Michael B
Director
BUY
2026-05-21 SECtraded 2026-05-20
2,562
$4.5K
-55.2%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 buys), the last on Apr 2, 2026.
  • -26.1% median (-14.9% mean) 90-day return after 6 previous buys.
  • The trade is 0.1% of the 3,291,101 shares held after it.
  • No other insider bought within 30 days.
  • 33 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hoffman Michael B bought about $4.5K of ANVS on May 20, 2026; 33 funds added in the latest 13F quarter.
Hoffman Michael B
Director
BUY
2026-05-21 SECtraded 2026-05-20
18,849
$33.9K
-55.2%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 buys), the last on Apr 2, 2026.
  • -26.1% median (-14.9% mean) 90-day return after 6 previous buys.
  • The trade is 0.6% of the 3,309,950 shares held after it.
  • No other insider bought within 30 days.
  • 33 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hoffman Michael B bought about $33.9K of ANVS on May 20, 2026; 33 funds added in the latest 13F quarter.
Hoffman Michael B
Director
BUY
2026-04-03 SECtraded 2026-04-02
713,800
$1.5M
-57.4%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Dec 8, 2025.
  • -36.4% median (-14.7% mean) 90-day return after 5 previous buys.
  • The trade is 21.7% of the 3,288,539 shares held after it.
  • No other insider bought within 30 days.
  • 33 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hoffman Michael B bought about $1.5M of ANVS on Apr 2, 2026; 33 funds added in the latest 13F quarter.
Hoffman Michael B
Director
BUY
2025-12-08 SEC
15,000
$63.6K
-77.6%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Nov 24, 2025.
  • -16.3% median (-8.3% mean) 90-day return after 4 previous buys.
  • The trade is 0.6% of the 2,574,739 shares held after it.
  • No other insider bought within 30 days.
  • 33 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hoffman Michael B bought about $63.6K of ANVS on Dec 8, 2025; 33 funds added in the latest 13F quarter.
23 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 18 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$142.8K over 180 days
more than 79% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
33 funds bought in last quarter
below 61% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
15.6% of the float short (float per yahoo 2026-10-26) · 6.0 days to cover · settled 2026-09-30
more than 82% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch ANVS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-50.5%12M
-52%+16%+84%+152%2025-102025-122026-022026-042026-062026-082026-10 2025-10-28 · Hoffman Michael B bought $2.0M2026-04-02 · Hoffman Michael B bought $1.5M2025-10-28 · Maccecchini Maria-Luisa bought $200.0K2025-12-08 · Hoffman Michael B bought $130.2K2025-11-24 · Hoffman Michael B bought $116.6K2025-11-24 · Hoffman Michael B bought $116.6K2026-05-20 · Hoffman Michael B bought $104.4K2025-12-08 · Hoffman Michael B bought $63.6K2025-11-24 · Hoffman Michael B bought $35.4K2025-11-24 · Hoffman Michael B bought $35.4K2025-11-21 · Hoffman Michael B bought $35.0K2025-11-21 · Hoffman Michael B bought $34.9K2026-05-20 · Hoffman Michael B bought $33.9K2025-11-14 · Hoffman Michael B bought $31.6K2025-11-24 · Hoffman Michael B bought $6.1K2025-11-24 · Hoffman Michael B bought $6.1K2026-05-20 · Hoffman Michael B bought $4.5K2025-11-24 · Hoffman Michael B bought $1.7K2025-11-24 · Hoffman Michael B bought $1.7K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ANVS: institutional holders (13F)

13F holdings, latest reported quarter
Empery Asset Management, LP
2,401,476 sh
$4.5M
MARSHALL WACE, LLP
1,842,339 sh
$3.4M
VANGUARD CAPITAL MANAGEMENT LLC
1,647,322 sh
$3.1M
TUDOR INVESTMENT CORP ET AL
1,357,134 sh
$2.5M
RENAISSANCE TECHNOLOGIES LLC
1,002,200 sh
$1.9M

Congress trades in ANVS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ANVS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ANVS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$62.5K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$192.2K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$13.0K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$732.6K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$237.0K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$2.3M position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 3
1 active
5
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $142.8K bought by insiders over 180 days, 33 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ANVS financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-703.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-227.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-288.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$0$0$0
Operating income-$29.7M-$26.7M-$45.0M-$25.5M
Net income-$28.9M-$24.6M-$56.2M-$25.3M
EPS (diluted)-1.40-2.31-6.23-3.10
Operating cash flow-$25.6M-$21.9M-$40.0M-$17.3M
Cash$19.5M$10.6M$5.8M$28.4M
SEC XBRL, fiscal years, as known on 2026-10-28

ANVS Stock Sonar score 4/7 axes

Find similar shapesCompare

ANVS ranks highest on insider conviction (67th percentile) and risk and compliance (59th), and lowest on profitability (7th), among Pharma & Biotech peers.

Profitability
7
Inputs
  • Return on equity-703.7% · 6 pct, sector of 545
  • Return on assets-227.7% · 9 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-288.6% · 6 pct, sector of 576
Insider conviction
67
Inputs
  • Net Form 4 buying (codes P and S), 180d$143K · 78 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
39
Inputs
  • Funds adding, latest quarter33 · 39 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
59
Inputs
  • Short interest, % of float+15.6% · 24 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+2.5% · 93 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ANVS filings, in plain words

Are Annovis Bio insiders buying or selling ANVS?

In the 180 days to 2026-10-28, Annovis Bio insiders were net buyers, a net $142.8K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Annovis Bio insiders were net buyers of ANVS, a net $142.8K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies